{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:04:00Z","timestamp":1791313440252,"version":"4.3.1"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Patients with underlying renal disease may be vulnerable to vancomycin-mediated nephrotoxicity and\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n                    bacteremia treatment failure. In light of recent data demonstrating the successful use of \u03b2-lactam plus daptomycin in very difficult cases of\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n                    bacteremia, we examined safety and clinical outcomes for patients who received daptomycin with or without concomitant \u03b2-lactams. We identified 106 patients who received daptomycin for\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n                    bacteremia, had mild or moderate renal insufficiency according to FDA criteria, and enrolled in the Cubicin Outcomes Registry and Experience (CORE), a multicenter registry, from 2005 to 2009. Daptomycin treatment success was 81%. Overall treatment efficacy was slightly enhanced with the addition of a \u03b2-lactam (87% versus 78%;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.336), but this trend was most pronounced for bacteremia associated with endocarditis or bone\/joint infection or bacteremia from an unknown source (90% versus 57%;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.061). Factors associated with reduced daptomycin efficacy (by logistic regression) were an unknown source of bacteremia (odds ratio [OR] = 7.59; 95% confidence interval [CI] = 1.55 to 37.2), moderate renal impairment (OR = 9.11; 95% CI = 1.46 to 56.8), and prior vancomycin failure (OR = 11.2; 95% CI = 1.95 to 64.5). Two patients experienced an increase in creatine phosphokinase (CPK) that resolved after stopping daptomycin. No patients developed worsening renal insufficiency related to daptomycin. In conclusion, daptomycin appeared to be effective and well tolerated in patients with\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n                    bacteremia and mild to moderate renal insufficiency. Daptomycin treatment efficacy might be enhanced with \u03b2-lactam combination therapy in primary endovascular and bone\/joint infections. Additional studies will be necessary to confirm these findings.\n                  <\/jats:p>","DOI":"10.1128\/aac.02192-12","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T23:21:37Z","timestamp":1355786497000},"page":"1192-1200","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":87,"title":["Multicenter Evaluation of the Clinical Outcomes of Daptomycin with and without Concomitant \u03b2-Lactams in Patients with Staphylococcus aureus Bacteremia and Mild to Moderate Renal Impairment"],"prefix":"10.1128","volume":"57","author":[{"given":"Pamela A.","family":"Moise","sequence":"first","affiliation":[{"name":"Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Amodio-Groton","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of California Los Angeles School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Lamp","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly L.","family":"Hoffman-Roberts","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Drug Discovery, University of California San Diego School of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min J.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Cubist Pharmaceuticals, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Schweitzer","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of California Los Angeles School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of California Los Angeles School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05022-11"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2138"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R158"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00168-11"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.07.025"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir078"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.10.013"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.17.1861"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/421092"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/524667"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir764"},{"key":"e_1_3_2_17_2","volume-title":"Cubicin (daptomycin for injection) current prescribing information","author":"Cubist Pharmaceuticals","year":"2010","unstructured":"Cubist Pharmaceuticals. November2010. Cubicin (daptomycin for injection) current prescribing information. Cubist Pharmaceuticals, Lexington, MA."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2871-2875.2004"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0b013e31822e9bcd"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir340"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-12"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01586-12"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00797-12"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.07.008"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.742"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(95)00082-E"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi971793d"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/420818"},{"key":"e_1_3_2_30_2","volume-title":"Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother","author":"Kullar R","year":"2012","unstructured":"KullarR McClellanI GeriakM SakoulasG. 2012. Efficacy and safety of daptomycin in the treatment of Gram-positive infections in patients with renal impairment, abstr. K-1631. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70200-2"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/423145"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis482"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00377-07"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/510396"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.11.4652-4660.1997"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.3013-3020.2001"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2872-2877.2001"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-44-3-157"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00080-9"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2000.0657"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02192-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02192-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:15:14Z","timestamp":1645463714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02192-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1128\/AAC.02192-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.02192-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"2012-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}